
LifeMD (LFMD) Stock Forecast & Price Target
LifeMD (LFMD) Analyst Ratings
Bulls say
LifeMD Inc. has demonstrated a solid positive outlook, highlighted by a 14% year-over-year growth in its Telehealth active subscriber base, reaching 310,818 at the end of the third quarter of 2025, which underscores the increasing demand for its telehealth services. The Telehealth segment generated $47.3 million in revenue, reflecting a significant 17.4% year-over-year increase and contributing to a total revenue of $60.2 million, showcasing an overall growth rate of 12.7% despite a slight miss from projections. Additionally, the company's recent initiatives, such as the introduction of Novo's GLP-1s at competitive pricing, along with the resurgence of the RexMD business and a focus on expanding product offerings, indicate a well-positioned strategy for sustained growth in the telehealth market.
Bears say
LifeMD Inc. reported a revenue of $60.2 million for the quarter, reflecting a 13% year-over-year increase, yet this figure fell short of various expectations, including a consensus estimate of $62.6 million. The company demonstrated a decline in its WorkSimpli segment, with revenue of $12.9 million, representing a 1.7% year-over-year decrease, which, alongside lowered full-year revenue guidance for 2025 to $192-$193 million, indicates possible ongoing struggles in the telehealth market. Additionally, challenges such as pressure from lower-cost competitor offerings, difficulty in acquiring and retaining patients, and a lack of profitability raise significant concerns about LifeMD's future growth potential and overall financial stability.
This aggregate rating is based on analysts' research of LifeMD and is not a guaranteed prediction by Public.com or investment advice.
LifeMD (LFMD) Analyst Forecast & Price Prediction
Start investing in LifeMD (LFMD)
Order type
Buy in
Order amount
Est. shares
0 shares